N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[5-(1-methylpyrrol-3-yl)benzimidazol-1-yl]phenyl]acetamide
C27H27N5O2 — CID 134154626
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[5-(1-methylpyrrol-3-yl)benzimidazol-1-yl]phenyl]acetamide
N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[5-(1-methylpyrrol-3-yl)benzimidazol-1-yl]phenyl]acetamide (PubChem CID 134154626) has the molecular formula C27H27N5O2 and a molecular weight of 453.55 g/mol. Its IUPAC name is N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[5-(1-methylpyrrol-3-yl)benzimidazol-1-yl]phenyl]acetamide.
Molecular Properties
| Compound Name | N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[5-(1-methylpyrrol-3-yl)benzimidazol-1-yl]phenyl]acetamide |
|---|---|
| PubChem CID | 134154626 |
| Molecular Formula | C27H27N5O2 |
| Molecular Weight | 453.55 g/mol |
| Exact Mass | 453.22 |
| IUPAC Name | N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[5-(1-methylpyrrol-3-yl)benzimidazol-1-yl]phenyl]acetamide |
| SMILES | Cn1ccc(-c2ccc3c(c2)ncn3-c2ccc(CC(=O)Nc3cc(C(C)(C)C)on3)cc2)c1 |
| InChI | InChI=1S/C27H27N5O2/c1-27(2,3)24-15-25(30-34-24)29-26(33)13-18-5-8-21(9-6-18)32-17-28-22-14-19(7-10-23(22)32)20-11-12-31(4)16-20/h5-12,14-17H,13H2,1-4H3,(H,29,30,33) |
| InChIKey | REQJIWOWTBYYLI-UHFFFAOYSA-N |
| XLogP | 5.50 |
| TPSA | 77.88 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 453.55 |
| LogP ≤ 5 | 5.50 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 134154626 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.